PR Newswire
SEATTLE
,
June 2, 2022
/PRNewswire/ — CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will provide a corporate overview at two upcoming investor conferences in
New York City
.
Presentation details:
Event: Jefferies Healthcare Conference
Date:
Friday, June 10, 2022
Time:
10:00 a.m. ET
Event: JMP Securities Life Sciences Conference
Date:
Wednesday, June 15, 2022
Time:
11:00 a.m. ET
Both presentations will be webcast live and available for replay from the Investors section of CTI BioPharma’s website at
www.ctibiopharma.com
.
About CTI BioPharma Corp.
We are a commercial biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. CTI has one FDA-approved product VONJO™ (pacritinib), a JAK2 and IRAK1, that spares JAK1. VONJO is approved for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 10
9
/L. CTI is conducting the Phase 3 PACIFICA study of VONJO in patients with myelofibrosis and severe thrombocytopenia as a post-marketing requirement.
VONJO™ is a trademark of CTI BioPharma Corp.
CTI BioPharma Investor Contacts:
Argot Partners
+212-600-1902
[email protected]
View original content to download multimedia:
https://www.prnewswire.com/news-releases/cti-biopharma-to-present-at-upcoming-june-conferences-301560347.html
SOURCE CTI BioPharma Corp.
